Willingness to take PhD students
Sarah Leonard's current work within the gynaeoncology research group has two main streams of enquiry. The first is focused on understanding the mechanisms of drug resistance in ovarian cancer and the second aims to improve the outcome of women with vulval disease. She is also part of the Birmingham Vulval Neoplasia Study Group. This group which focuses on improving the outcome of women with vulval disease is currently running an NIHR funded phase 2 placebo controlled trial of the polyphenol, epigallocatechin-3-gallate (EGCG), in women with VIN, and for which she is the scientific translational lead.
Dr Leonard has co-supervised two PhD students. One, an SPR in gynaecology, was exploring how high-risk HPV types modulate the expression of the DNA methyltransferases using a virus replication model, whilst the other, an SPR in pathology, was investigating the site of HPV latency while at the same time examining the expression of these epigenetic regulators in cervical and vulval neoplasia.